Cytokinesis and cancer: polo loves ROCK'n' Rho(A) by Li, Jing et al.
  
                              
 
 
 
 
 
 
www.jgenetgenomics.org 
DOI: 10.1016/S1673-8527(09)60034-5 
JOURNAL OF
GENETICS AND
GENOMICS
J. Genet. Genomics 37 (2010) 159172 
Cytokinesis and cancer: Polo loves ROCK’n’ Rho(A) 
Jing Li *, Jue Wang, Hong Jiao, Ji Liao, Xingzhi Xu * 
Laboratory of Cancer Biology, College of Life Science, Capital Normal University, Beijing 100048, China
Received for publication 24 December 2009; revised 8 February 2010; accepted 9 February 2010 
Abstract 
Cytokinesis is the last step of the M (mitosis) phase, yet it is crucial for the faithful division of one cell into two. Cytokinesis failure is 
often associated with cancer. Cytokinesis can be morphologically divided into four steps: cleavage furrow initiation, cleavage furrow 
ingression, midbody formation and abscission. Molecular studies have revealed that RhoA as well as its regulators and effectors are im-
portant players to ensure a successful cytokinesis. At the same time, Polo-like kinase 1 (Plk1) is an important kinase that can target many 
substrates and carry out different functions during mitosis, including cytokinesis. Recent studies are beginning to unveil a closer tie be-
tween Plk1 and RhoA networks. More specifically, Plk1 phosphorylates the centralspindlin complex Cyk4 and MKLP1/CHO1, thus re-
cruiting RhoA guanine nucleotide-exchange factor (GEF) Ect2 through its phosphopeptide-binding BRCT domains. Ect2 itself can be 
phosphorylated by Plk1 in vitro. Plk1 can also phosphorylate another GEF MyoGEF to regulate RhoA activity. Once activated, 
RhoA-GTP will activate downstream effectors, including ROCK1 and ROCK2. ROCK2 is among the proteins that associate with Plk1 
Polo-binding domain (PBD) in a large proteomic screen, and Plk1 can phosphorylate ROCK2 in vitro. We review current understandings 
of the interplay between Plk1, RhoA proteins and other proteins (e.g., NudC, MKLP2, PRC1, CEP55) involved in cytokinesis, with par-
ticular emphasis of its clinical implications in cancer. 
Keywords: Polo-like kinase 1; RhoA GTPase; Rho kinase; cytokinesis 
 
Introduction
Cytokinesis, the last step of the M (mitosis) phase, in-
volves physically dividing the cytoplasm of a single cell to 
form two daughter cells. This is a crucial step in cell cycle 
and has been widely studied in many model organisms: 
budding yeast, fission yeast, Drosophila, Caenorhabditis 
elegans, Xenopus, Dictyostelium, plants, and vertebrate 
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cells (Normand and King, 2010). In animal cells the con-
tractile ring carries out the cytokinesis step and is com-
posed of the actin cytoskeleton and its motor molecule, 
myosin II (referred to as myosin in this review). But what 
are the regulatory proteins for the spatial and temporal 
events of cytokinesis? The small GTPase of Rho (Ras ho-
mologous) families are among the first proteins to be iden-
tified. Mammalian Rho GTPases comprise 20 intracellular 
signaling molecules, and can be subdivided into three ma-
jor subsets: Rho, Rac and Cdc42 (Narumiya and Yasuda, 
2006). They cycle between the inactive GDP-bound form 
and the active GTP-bound form. The cycling of Rho 
GTPases between these two states is regulated by three 
sets of proteins, guanine nucleotide-exchange factors 
(GEFs), GTPase-activating proteins (GAPs) and guanine 
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nucleotide-dissociation inhibitors (GDIs). All three subsets 
of Rho GTPases are implicated in cytokinesis in different 
organisms, but RhoA is the most critical in mammalian 
cells. During cytokinesis, both induction and progression 
of the contractile ring depend on RhoA activation (Piekny 
et al., 2005). 
Besides the cytoskeleton system and its interacting Rho 
GTPase, a successful cytokinesis also requires key protein 
kinases and signaling networks to coordinate the position 
of chromosomes in relative of the cell cortex. Cyclin-     
dependent kinases (Cdks), Aurora B and Polo-like kinases 
(Plks) are important kinases that not only regulate cytoki-
nesis, but also are crucial regulators of other mitotic events 
(Glotzer, 2005; Barr and Gruneberg, 2007). There are sev-
eral conserved Plks in humans, and we will only focus on 
Plk1 in this review, since it is believed that the major func-
tion is attributed to Plk1. Recently, some substrates of Plk1 
have been identified to be involved in cytokinesis, includ-
ing PRC1 (Protein Regulator of Cytokinesis 1) (Neef et al., 
2007), CEP55 (CEntrosome Protein 55) (Fabbro et al., 
2005), NudC (Nuclear-distribution gene C) (Zhou et al., 
2003) and MKLP2 (mitotic-kinesin-like protein 2) (Neef et 
al., 2003). Also among these substrates are the Rho pro-
teins: Rho GEF Ect2 (Epithelial cell transforming gene 2) 
(Niiya et al., 2006), Rho GAP HsCyk-4 (Burkard et al., 
2009; Wolfe et al., 2009) and MKLP1/CHO1 (Liu et al., 
2004). Moreover some of the RhoA downstream effectors 
are found to bind to the Plk1 Polo-box domain (PBD), 
including the Rho-associated coiled-coil-forming kinase 
(ROCK) (Lowery et al., 2007). ROCK is also phosphory-
lated by Plk1 in vitro (Lowery et al., 2007). Thus Plk1 and 
Rho GTPases are intricately linked with each other during 
the cytokinesis process. 
It has been widely known that cytokinesis failure results 
in polyploidy and increased genome instability, which are 
frequently observed in cancer cells. In fact, Plk1, RhoA 
and their interacting proteins are all reported to be deregu-
lated in some cancers. As more and more proteins involved 
in tumorigenesis are found to play a role in cytokinesis, 
such as Chk1 (Peddibhotla et al., 2009) and BRCA2 
(Daniels et al., 2004), it has become apparent that cytoki-
nesis and cancer are interconnected. This review will focus 
on these recent new findings in vertebrate cells and will 
explore its potential implication in cancer therapy, but ob-
servations from yeast and other organisms are discussed 
where appropriate. 
The structure of Plk1 and its function in cytokinesis 
Plk1 is a serine/threonine kinase that orchestrates the 
mitotic process. It was first discovered in Drosophila, as 
polo mutants fail to undergo a normal mitosis (Sunkel and 
Glover, 1988). And Plk1 homologues have been identified 
in many eukaryotes (Table 1). Plk1 has been shown to play 
key roles during different stages of mitosis, including mi-
totic entry, bipolar spindle formation, chromosome segre-
gation and cytokinesis (Barr et al., 2004; van de Weerdt 
and Medema, 2006). 
The structure of Plk1 is conserved across different spe-
cies, with a serine/threonine kinase domain at its 
N-terminus and a regulatory domain, the PBD, at its 
C-terminus (Fig. 1A). Plk1 is activated by phosphorylation 
at Thr210 within the kinase domain. All Plks have a con-
served PBD, and PBD has been identified as a phosphopep-
tide-binding motif (Elia et al., 2003). Indeed, studies 
Table 1 
Homologues of relevant proteins in eukaryotes 
 Saccharomyces cerevisiae 
Schizosaccharomyces
pombe
Drosophila 
melanogaster
Caenorhabditis 
elegans Mammals 
Polo-like kinase 1 Cdc5 Plo1 Polo Plc1 Plk1 
Rho A Rho1 Rho1 Rho Rho A Rho A 
ROCK NA NA Rok/Drok LET-502 ROCK 
RhoGEF/Ect2 Tom2, Tus1 NA Pebble(Pbl) Let-21 Ect2 
GAP NA NA Tumbleweed/MgcGAP50C Cyk-4 MgcRacGAP/HsCyk-4 
MKLP1 NA NA Pavarotti ZEN-4 MKLP1/CHO1/Kif23 
MYPT1 NA NA MYPT/Mbs MEL-11 MYPT1 
NA: no homologs available. 
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Fig. 1.  Diagrams of protein structures. A: Plk1 consists of a serine/threonine kinase domain at its N-terminus and a regulatory domain and the polo box 
domain (PBD) at its C-terminus. B: Ect2 consists of two phosphopeptide-binding BRCT domains at its N-terminus and a tandem array of Dbl-homology 
(DH) domain and pleckstrin-homology (PH) domain at its C-terminus C: Cyk4 consists of an N-terminal coiled-coil domain and a C-terminal RhoGAP 
domain. D: MKLP1 consists of an N-terminal motor domain and a short coiled-coil region. E: PRC1 contains a central-spindle targeting at its N-terminus, 
and a central microtubule binding domain. 
 
of Plk1 and its substrates have established a common 
theme that Plk1 can dock to specific phosphorylated tar-
gets through its PBD domain. 
Early evidence showing Plk1’s function in cytokinesis 
comes from S. pombe Plo1 (Ohkura et al., 1995). Plo1 
activity correlates with division septum formation, as up- 
or down-regulation of Plo1 both affects the division sep-
tum. The study of the role of Plk1 in mammalian cell cy-
tokinesis is hampered by the fact that Plk1 depletion 
causes early mitotic defects. But overproduction of Plk1 
results in multinucleation in mammalian cells, indicative 
of cytokinesis failure. Plk1’s substrates during cytokinesis 
include MKLP2 and NudC. Both MKLP2 and NudC have 
motor protein activity (MKLP2 is a kinesin and NudC is a 
component of the dynein), and both localize to the central 
spindle. Plk1 phosphorylates MKLP2 at Ser528 and phos-
phorylated MKLP2 binds with Plk1 PBD (Neef et al., 
2003). When this phosphorylation is blocked, cells show 
cytokinesis defects. NudC RNA interference (RNAi) re-
sults in multinucleation and midbody arrest (Zhou et al., 
2003). NudC is phosphorylated by Plk1 at Ser274 and 
Ser326 in vitro, and phosphorylation-deficient mutants will 
not rescue the cytokinesis defects of NudC RNAi.  
Direct evidence of Plk1’s involvement in RhoA medi-
ated cytokinesis pathway comes from chemical studies 
(Brennan et al., 2007; Burkard et al., 2007; Petronczki et 
al., 2007; Santamaria et al., 2007). Burkard et al. (2007) 
disrupted Plk1 and substituted it with a mutant Plk1as. 
Plk1as has an enlarged catalytic pocket that can accommo-
date bulky purine analogs (e.g., 1-NM-PP1, or 3-MB-PP1). 
Since these analogs will not fit into the wild-type Plk1, 
they can specifically block the activity of Plk1as. When the 
purine analogs are applied during anaphase, Plk1’s re-
cruitment to the central spindle is blocked, which prevents 
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cleavage furrow formation and cell division. Closer ex-
amination reveals that RhoA localization to the cleavage 
cortex is disrupted, and so are the RhoA downstream tar-
gets including citron kinase and anillin. Ect2’s recruitment 
to the equatorial cortex and central spindle is also affected. 
Another method directly uses Plk1’s small-molecule in-
hibitor BI 2536 (Petronczki et al., 2007). BI2536 treatment 
abolishes Ect2 localization to the central spindle, but Cyk4 
and Mklp1 are not affected. Other inhibitors such as 
BTO-1 and ZK-Thiazolidinone (TAL) have the same effect 
(Brennan et al., 2007; Santamaria et al., 2007). These 
studies reveal that Plk1 plays important roles during the 
last stages of cell cycle.  
Plk1 and RhoA: caught in the act of cytokinesis 
There are four morphological stages of cytokinesis: di-
vision site positioning and cleavage furrow initiation; 
cleavage furrow ingression; midbody formation; and ab-
scission (Fig. 2). We are going to review the roles of Plk1, 
RhoA and their relationship at each distinct stage. Table 2 
summarizes the currently known Plk1 substrates and in-
teracting proteins involved in cytokinesis. 
 
Fig. 2.  The mitotic cell cycle. A: HeLa cells in different phases of mitosis were stained with anti-tubulin (green) antibodies and DAPI. B: Schematic 
diagrams of the spindle assembly in relative to the chromosomes during mitosis. Red circle demarcates the contractile ring. 
Table 2 
Some of the known Plk1 substrates and interacting proteins in cytokinesis and their phosphorylation sites 
Protein Phosphorylation site Biological function of phosphorylation Reference 
Rock2 Multiple sites Binds with Plk1 PBD, activates ROCK2 activity Lowery et al., 2007 
MgcRacGAP/HsCyk-4 
 
Ser157 
 
Binds to the BRCT domain of Ect2, thus recruiting Ect2 to the midzone 
 
Burkard et al., 2009;
Wolfe et al., 2009 
CHO1/MKLP1 Ser904, Ser905 Binds with Plk1 PBD, essential for cytokinesis Liu et al., 2004 
MyoGEF Thr574 Regulates RhoA activity Asiedu et al., 2008 
MKLP2 Ser528 Binds with Plk1 PBD, essential for cytokinesis Neef et al., 2003 
NudC Ser274,Ser26 Essential for cytokinesis Zhou et al., 2003 
Cep55 Ser436 Essential for cytokinesis Fabbro et al., 2005 
Ect2 Thr412 (by Cdk1) Binds with Plk1 PBD, regulates RhoA recruitment and activation Niiya et al., 2006 
PRC1 Thr578, Thr602 Binds with Plk1 PBD in an anaphase-specific manner, essential for cytokinesis Neef et al., 2007 
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Division site positioning and cleavage furrow initiation 
In different organisms, division site positioning is es-
tablished at different points in the cell cycle. Cytokinesis 
initiation in various systems was reviewed by Oliferenko 
et al. (2009). In animal cells the site of cell division is 
chosen during mitosis. More specifically, it is determined 
in late anaphase and/or telophase. During this stage, the 
mitotic spindle pulls the sister chromatids apart, and in the 
mean time emits signals to initiate cytokinesis. Earlier 
micromanipulation experiments show that when mitotic 
spindle orientation in star fish eggs is changed, the position 
of the cortical contractile ring is also altered (Rappaport 
and Ebstein, 1965), indicating that the spindle position 
specifies the cleavage furrow formation. The mitotic spin-
dle consists of the interdigital central spindle and polar 
astral microtubules. Central spindle may send positive 
signals to the cell cortex nearest to the spindle midzone to 
specify cleavage sites, while the polar astral spindle may 
inhibit the cortical contractility. These distinct groups of 
spindles cooperate together to signal the furrowing site 
(Bringmann and Hyman, 2005; Glotzer, 2009). 
 How can the spindle microtubule control the cortical 
contractility? The answer lies in the small GTPase RhoA. 
RhoA is crucial for furrowing, as biochemical inactivation 
or depletion of RhoA will lead to cleavage furrow forma-
tion failure (Piekny et al., 2005). Activated RhoA localizes 
to a narrow cortical zone within the cleavage furrow, and 
spindle displacement can perturb this localization pattern 
(Bement et al., 2005). Activated GTP-bound RhoA in turn 
induces F-actin assembly and activates myosin function, 
thus promoting the contractility of cell cortex. The speci-
ficity of RhoA activation is achieved by localizing specific 
RhoA regulators on the microtubules. The regulators that 
have been identified so far include Ect2, Cyk4, MyoGEF 
(myosin-interacting GEF), p0071, and phospholipids (de-
tails will be discussed below). 
Ect2 was originally isolated as a proto-oncogene from 
epithelial cells that are capable to transform (Miki et al., 
1993). The C-terminus of Ect2 contains a tandem array of 
Dbl-homology (DH) domain and pleckstrin-homology (PH) 
domain (Fig. 1B). It is the C-terminus that confers Ect2 the 
ability to catalyze guanine nucleotide exchange on RhoA 
(Saito et al., 2004). Besides the DH/PH cassette, Ect2 con-
tains N-terminal tandem BRCT (BRCA1-C Terminal) do-
mains, and the central S domain that contains the nuclear 
localization signals. The BRCT domains associate with the 
C-terminal DH/PH domain and blocks its ability of gua-
nine nucleotide exchange (Saito et al., 2004). Ect2 local-
izes in the nucleus during interphase in an inactive state, 
becomes activated and localizes to the mitotic spindles 
during metaphase, and finally appears at the midbody 
structure during cytokinesis. Both Ect2 antibody injection 
and Ect2 RNAi inhibits cytokinesis and leads to multinu-
cleated cells (Saito et al., 2004). These results demonstrate 
that Ect2 plays a crucial role to activate RhoA. 
How is Ect2 recruited to the central spindle? It turns out 
that the centralspindlin complex recruits Ect2. The 
tetrameric centralspindlin complex is composed of a dimer 
of the kinesin 6 protein MKLP1 (also known as Kif23) and 
a dimer of the GAP Cyk4 (also known as RacGAP1 or 
MgcRacGAP) (Mishima et al., 2002). The interaction be-
tween MKLP1 and Cyk4 is evolutionarily conserved, and 
they localize to the central spindle in an inter-dependent 
manner, where they promote the microtubule bundling 
(Mishima et al., 2002). The N-terminus of Cyk4 binds to the 
neck linker of MKLP1 (Fig. 1, C and D), and assembles into 
a stable centralspindlin complex (Pavicic-Kaltenbrunner et 
al., 2007). Cyk4 binds to and stabilizes activated Ect2, al-
lowing Ect2 to interact with RhoA (Yuce et al., 2005). As a 
result, Ect2 activates RhoA and signals to the overlying 
equatorial cortex, leading to contractile ring formation and 
cleavage furrow ingression. The centralspindlin complex 
travels along central spindles as higher-order clusters and 
accumulates at the midbody. Centralspindlin clustering is 
critical for microtubule bundling and motility, as well as 
midbody formation (Hutterer et al., 2009). When the cen-
tralspindlin complex localizes to the central spindle, it re-
stricts Ect2 within the narrow zone, leading to RhoA’s 
narrow activation. When this localization pattern is dis-
rupted, RhoA will be activated in a much broader range, 
and cells will fail to form a furrow. In Xenopus, 
MgcRacGAP not only anchors active RhoA to the activity 
zone, but also promotes local RhoA inactivation that pro-
vides constant Rho to the GTPase cycle (Miller and Be-
ment, 2009), consistent with earlier findings that the GAP 
activity is essential for cytokinesis in mammals (Hirose et 
al., 2001). 
It may seem paradoxical that both Rho GEF and GAP 
are required for RhoA activation. When MgcRacGAP an-
tisense morpholino oligonucleotides are applied, the 
Xenopus embryos display cytokinesis defects as well as a 
broader zone of RhoA activity (Miller and Bement, 2009). 
Only wild-type MgcRacGAP, but not a GAP activity mu-
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tant allele of MgcRacGAP can rescue the defects, suggest-
ing that the GAP activity is required for RhoA inhibition, 
which in turn is required for cytokinesis. Thus the “Rho 
flux model” speculates that a weaker GAP activity than the 
GEF activity at the cleavage furrow will lead to RhoA ac-
tivation, but both the GAP and GEF are required. The 
other “Rac inactivation” model states that RacGAP is re-
quired to inhibit Rac GTPase and activate RhoA at the 
same time (Canman et al., 2008). Further experiments may 
reconcile these two different models, but there is no doubt 
that GAP is essential for RhoA activity. 
Recent investigations show that both GEF Ect2 and 
Cyk4 are Plk1 substrates. Ect2 is phosphorylated during 
the G2/M transition (Niiya et al., 2006). In vitro Ect2 can 
be phosphorylated by Cdk1 and Plk1. Cdk1 phosphoryla-
tion at Thr412 creates a phosphospecific binding pocket 
(SpTP) for Plk1 PBD (Niiya et al., 2006). When the 
Thr412 residue is mutated to Ala, RhoA activation is di-
minished. In contrast, the phosphomimic Ect2 T412D mu-
tant still exhibits significant action of RhoA. Ect2 over-
production induces cortical hyperactivity that leads to cell 
death, but Ect2-T412A overproduction has no such effect 
(Niiya et al., 2006). Furthermore, this interaction is not 
limited to mammalian cells. In budding yeasts two RhoA 
GEFs (Tus1 and Rom2) are both substrates of Cdc5 in 
vitro and in vivo (Yoshida et al., 2006). Thus it seems a 
conserved pathway for Plk1 to regulate the recruitment and 
activation of RhoA by regulating Rho GEF’s localization 
to the division site. 
Since the interaction between Ect2’s BRCT domains and 
Cyk4 is dependent on phosphorylation (Yuce et al., 2005), 
there has been speculation that Cyk4 might be phosphory-
lated prior to binding to Ect2’s BRCT domains, which bind 
phosphopeptides. Indeed, two independent investigations 
show that Plk1 specifically binds and phosphorylates Cyk4 
at Ser157, thus creating a docking site for the Ect2 BRCT 
domains (Burkard et al., 2009; Wolfe et al., 2009). When 
Ser157 is mutated to a nonphosphorylated form, Ect2 fails 
to localize at the midzone, leading to cleavage furrowing 
errors (Burkard et al., 2009; Wolfe et al., 2009). 
Besides Ect2, RhoA also has other regulators, including 
GEF MyoGEF (Wu et al., 2006), the armadillo protein 
p0071 (Wolf et al., 2006) and phospholipids (Yoshida et al., 
2009). MyoGEF also contains the DH and PH domains. 
MyoGEF disruption by RNAi results in binucleated and 
multinucleated cells and decreased RhoA activation (Wu et 
al., 2006). MyoGEF localizes to the central spindle, and 
interacts with Ect2, and MyoGEF RNAi leads to Ect2 and 
RhoA mislocalization during cytokinesis (Asiedu et al., 
2009). MyoGEF and Plk1 colocalize at the spindle pole 
and central spindle, and MyoGEF localization is dependent 
on Plk1 (Asiedu et al., 2008). Plk1 phosphorylates Myo-
GEF on Thr574 in vitro (Asiedu et al., 2008). In vivo ex-
periments show that the MyoGEF T574A mutant dramati-
cally decreases MyoGEF phosphorylation. MyoGEF 
T574A displays decreased GEF activity towards RhoA, 
suggesting that Plk1 can regulate RhoA activity through 
phosphorylating MyoGEF.  
The armadillo protein p0071 localizes at the midbody 
(Wolf et al., 2006). Its upregulation or downregulation 
leads to cytokinesis defects and induces apoptosis. It turns 
out that p0071 interacts with Ect2 and RhoA, and altera-
tion of p0071 expression deregulates RhoA activity (Wolf 
et al., 2006). p0071 localization is dependent on kinesin-II 
member Kif3b (Keil et al., 2009). 
Evidence that phospholipids promote RhoA localization 
comes from the budding yeast. During septation and abscis-
sion in the yeast cells, Rho1 bud neck targeting requires that 
the Rho1 polybasic sequence binds to acidic phospholipids, 
including phosphatidylinositol 4,5-bisphosphate (PIP2) 
(Yoshida et al., 2009). In animal cells, this mechanism 
might be further facilitated by phosphatidylinositol 3,4,5- 
trisphosphate, which is not present in the budding yeast. 
Cleavage furrow ingression 
After RhoA is temporally and locally activated, it will 
recruit and activate downstream effectors to induce cleav-
age furrow ingression (Fig. 3). Downstream targets include 
proteins to stimulate actin polymerization, as well as 
ROCK and citron kinase that stimulate myosin activity 
(Matsumura, 2005). 
Myosin comprises two heavy chains, two essential light 
chains and two regulatory myosin light chains (MLC). 
MLC Ser19 phosphorylation stimulates myosin ATPase 
activity, and Thr18 phosphorylation promotes myosin as-
sembly (Matsumura, 2005). During mitosis, MLC is 
phosphorylated at Ser1, 2 and 9 by CDK1 to inhibit my-
osin ATPase activity. CDK1 deactivation at anaphase al-
lows MLC dephosphorylation at these sites. Thus specific 
MLC phosphorylation site controls contractile ring assem-
bly. Expression of a nonphosphorylation mutant of MLC 
in fly and culture cells both results in cytokinesis failure 
(Jordan and Karess, 1997; Komatsu et al., 2000). 
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Fig. 3.  Regulation of the contractile ring formation by the RhoA 
GTPase. RhoA is activated by GEF (Ect2, MyoGEF) and inactivated by 
GAP (Cyk4). RhoA-GTP is concentrated at the cleavage site and induces 
actin filament assembly. In the meantime, RhoA activates downstream 
effectors (ROCK and citron kinase), which induce MCL phosphorylation 
and thereby myosin II filament formation. Thus the contractile ring, which 
is composed of the actin filaments and myosin II, is assembled. In this 
diagram, proteins marked in bold are currently known Plk1 substrates. 
 
MLC phosphorylation is controlled by three kinases: 
ROCK, citron kinase, MLCK (Myosin Light Chain 
Kinase), and also reversibly controlled by myosin phos-
phatase. ROCK localizes to the cleavage furrow, and inhi-
bition of ROCK with Y-27632 causes cleavage delay, but 
not affecting cytokinesis initiation and completion 
(Kosako et al., 2000). Mammalian cells have two ROCK 
isoforms: ROCK1 (RokE) and ROCK2 (RokD). Knock-
down of either ROCK1 or ROCK2 in mice does not display 
cytokinesis defects (Thumkeo et al., 2003; Shimizu et al., 
2005), which might be caused by the redundancy between 
these two kinases. Double-knockout mice will help to elu-
cidate the function of ROCK in cytokinesis. 
Both cytology and biochemistry studies show that Plk1 
and ROCK2 interact. Plk1 and ROCK2 colocalize at the 
midbody during cytokinesis (Lowery et al., 2007). Plk1 
coimmunoprecipitates with ROCK2 in a phosphoryla-
tion-dependent and mitosis-specific manner. Plk1 can 
phosphorylate ROCK2 in vitro, and phosphorylated 
ROCK2 interacts with Plk1 PBD (Lowery et al., 2007). 
Plk1 and RhoA act in a synergistic fashion to activate 
ROCK2 in vitro and in vivo. 
The second kinase, citron kinase, also localizes in the 
cleavage furrow. Its overproduction upregulates cortex 
contractility, suggesting that it positively regulates myosin 
activity (Madaule et al., 1998). It phosphorylates MLC at 
Ser19/Thr18 both in vitro and in vivo (Yamashiro et al., 
2003). Citron kinase knockout mice complete embryonic 
development, but some neuronal precursor cells display 
abnormal cytokinesis and massive apoptosis (Di Cunto et 
al., 2000). These cells express ROCK proteins at the nor-
mal level, suggesting that although ROCK and citron 
kinase might be redundant in activating myosin, they may 
have other distinct regulatory function. 
MLCK is a third kinase that can phosphorylate MLC in 
the cleavage furrow. It is activated by Ca2+/calmodulin and 
also by phosphorylation. MLCK inhibition in cultured 
mammalian cells leads to cytokinesis failure (Normand 
and King, 2010). MLCK might also be regulated by phos-
pholipids, because PIP2 hydrolysis is important for inosi-
tol-1,4,5-trisphosphate (IP3)-induced calcium release 
(Wong et al., 2007). 
The only known phosphatase of MLC is myosin phos-
phatase, which consists of a targeting subunit MYPT1 
(Myosin Phosphatase Targeting Subunit 1), a catalytic 
subunit PP1Cȕ and an additional small subunit (Baumann 
et al., 2007; Matsumura and Hartshorne, 2008). During 
anaphase, both ROCK and Aurora B kinase phosphorylate 
MYPT1 in the furrow to inhibit its phosphatase activity 
(Kawano et al., 1999; Yokoyama et al., 2005), which may 
lead to increase of MLC phosphorylation at the cleavage 
furrow and signal for cytokinesis. MYPT1 is recently re-
ported to be phosphorylated by Cdk1 in a mitosis-specific 
fashion, which generates a binding motif for Plk1 PBD 
(Yamashiro et al., 2008). MYPT1 antagonizes Plk1 activity, 
as MYPT1 depletion increases Plk1-T210 phosphorylation 
(Yamashiro et al., 2008). But whether this interaction 
functions in cytokinesis remains to be elucidated. MYPT1 
is recently found to be a regulatory subunit of ser-
ine/threonine-protein phosphatase 6 catalytic subunit 
(PP6C) and function in the homologous recombination 
pathway (unpublished data). It is a possible scenario that 
PP6C is targeted by MYPT1 to dephosphorylate MLC.  
Formation of the midbody 
Cleavage furrow ingression continues until the actomy-
osin contractile ring comes into close proximity to the cen-
tral spindle. Although proteomic approaches have been 
used to identify the midbody components (Skop et al., 
2004; Chen et al., 2009a), its precise function is not yet 
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understood in detail. It is hypothesized that the midbody 
maintains a state of constriction until abscission is com-
pleted. 
The centralspindlin complex also plays an essential role 
in this step. MKLP1 has a splice variant called CHO1. 
CHO1 is shown to be required for midbody formation in 
mammalian cells in RNAi studies (Matuliene and Kuri-
yama, 2002, 2004). CHO1 contains an extra F-actin inter-
acting domain, indicating that it may function to link the 
actin with the centralspindlin complex. Plk1 interacts with 
CHO1 during anaphase and telophase, and the PBD do-
main of Plk1 is responsible for this association (Liu et al., 
2004). Also needed is the stalk domain of CHO1. When 
CHO1 is depleted, Plk1 fails to localize at the midbody, and 
cells turn multinucleated with more centrosomes. Plk1 can 
phosphorylate CHO1 in vitro, and Ser904 and Ser905 are the 
major phosphorylation sites. When a non-phosphorylated 
form of CHO1 is expressed, cells display cytokinesis de-
fects (Liu et al., 2004).  
Some proteins that localize to the midbody have been 
studied in detail, and one of them is PRC1. It is critical for 
midbody formation in mammalian cells. In anaphase, 
PRC1 localizes to the central spindle where its main func-
tion is to bundle microtubules (Mollinari et al., 2002). De-
pletion of PRC1 leads to abscission failure without affect-
ing the cleavage furrow ingression. Domain analysis re-
veals that PRC1 has two separate domains that target 
PRC1 to distinct subcellular structures (Mollinari et al., 
2002) (Fig. 1E). Its N-terminus interacts with kinesin Kif4 
and is targeted to the midzone, where PRC1 recruits the 
centralspindlin complex and other kinesin proteins (Zhu 
and Jiang, 2005). On the contrary, the central region of 
PRC1 is required for microtubule binding and bundling 
activity (Mollinari et al., 2002). In metaphase CDK1 
phosphorylates PRC1 at T470 and T481 (Neef et al., 2007). 
These phosphorylation events prevent Plk1 binding. As 
CDK1 activity decreases in anaphase, Plk1 phosphorylates 
PRC1 at T578 and T602, creating its own docking site. 
Thus PRC1 binds to Plk1 in an anaphase-specific manner, 
which is essential for cytokinesis. Consistent with this, 
CDK1 phosphorylation-deficient mutations result in pre-
mature binding with Plk1 and mitotic block (Neef et al., 
2007).  
Plk1 also regulates the katanin protein that severs 
microtubules at the midbody and functions both in mitosis 
and meiosis (McNally et al., 2002). In Xenopus, Plx1 
colocalizes with katanin at spindle poles in vivo and puri-
fied Plx1 increases the microtubule-severing activity of 
katanin in vitro (McNally et al., 2002). Katanin is also es-
sential for post-mitotic differentiation events in vertebrate 
neurons and in Arabidopsis. 
Abscission
Abscission is the final step of cytokinesis. During this 
stage, the microtubule bundles start to compact and disap-
pear (Fig. 2). The centrosome protein Cep55, which local-
izes to the midbody in a centralspindlin-dependent manner, 
is essential for this step (Zhao et al., 2006). The absence of 
Cep55 will lead to midbody formation defects (Zhao et al., 
2006). Cdk1/Erk2 phosphorylates Cep55 at Ser425/Ser428, 
which is required for Cep55’s interaction with Plk1. Plk1 
further phosphorylates Cep55 at Ser436. When Ser436 is 
mutated, cells display cytokinesis failure (Fabbro et al., 
2005). Cep55 also has microtubule-bundling function that 
is essential for the midbody formation (Zhao et al., 2006). 
Recently, it was shown that the peptidyl-prolyl isomerase 
Pin1 enhances the Plk1-dependent phosphorylation of 
Cep55 (van der Horst and Khanna, 2009). Moreover, 
Cep55 is stabilized post-translationally during mitosis in a 
Pin1-dependent manner, and Cep55’s stable protein level 
is essential for proper execution of cytokinesis (van der 
Horst et al., 2009).  
Because abscission involves the membrane organization 
changes, the membrane trafficking system is crucial for 
this step. These include the secretory pathway, the endo-
cytic pathway and the ESCRT machinery (Endosomal 
Sorting Complex Required for Transport) (Normand and 
King, 2010). Depletion of components of these pathways 
has been shown to lead to cytokinesis defects. Alix and 
Tsg101 (Tumor-Susceptibility Gene 101) are components 
of the ESCRT network, and they are recruited to the mid-
body by interacting with Cep55 (Carlton and Mar-
tin-Serrano, 2007).  
Implication of cytokinesis in cancer 
It has been widely known that cytokinesis failure will 
lead to polyploidy. But some body tissues are polyploid by 
nature. For instance, megakaryocyte (MK) cells are unique 
among mammalian cells in that they are the naturally 
polyploid hematopoietic cells that can give rise to platelets. 
Polyploidization is intrinsic to this differentiation event. 
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MK cell polyploidization occurs by endomitosis, which  
was recently shown to be caused by late cytokinesis failure  
related to defects in Rho/Rock signaling (Lordier et al.,  
2008). Thus in certain tissues Rho and ROCK can be the  
targets of physiological regulation. 
Apart from the naturally polyploid cells, failure of cy- 
tokinesis in normal cells can cause cell death or lead to  
genome amplification, which is characteristic of many  
cancers. When diploid and tetraploid cultures are isolated  
from p53-null cells, only the tetraploid cells are trans- 
formed in vitro after carcinogen exposure (Fujiwara et al.,  
2005). In addition, only the tetraploid cells will give rise to  
malignant mammary epithelial cancers after transplanted  
into nude mice. These results indicate that tetraploidy,  
which is frequently the product of cytokinesis failure, can  
promote tumor development in p53-null cells. Further  
studies show that the p53-deficient tetraploid cells display  
aneuploidy, genomic rearrangements and amplification  
(Fujiwara et al., 2005). Thus, cytokinesis failure, poly- 
ploidization and erroneous chromosome segregation may  
form a positive feedback loop to promote tumorigenesis. 
Indeed, a lot of DNA damage checkpoint proteins are 
recently shown to be involved in cytokinesis. These pro-
teins have been shown to be implicated in cancer. For in-
stance, Chk1 is a critical component of the DNA damage 
checkpoint network that functions in DNA replication, 
intra-S phase and the G2/M phase transition. Chk1+/ mice 
display Aurora B mislocalization. Moreover, Chk1 abroga-
tion leads to cytokinesis regression and binucleation 
(Peddibhotla et al., 2009). Another example is BRCA2, 
which is a breast cancer susceptibility protein. People car-
rying germ-line mutations inactivating BRCA2 are pre-
disposed to breast cancer. RNAi experiments in HeLa cells 
to knock down BRCA2 lead to cytokinesis defects (Daniels 
et al., 2004). Furthermore, cytokinesis failure is also ob-
served when BCCIP1, a BRCA2-interacting protein, is 
downregulated (Meng et al., 2007).  
More proteins are found to be at the intersection of cy- 
tokinesis and tumorigenesis. The peptidyl-prolyl isomerase  
Pin1 that was mentioned above localizes to the midbody  
ring and regulates the final stages of cytokinesis by bind- 
ing to Cep55 (van der Horst and Khanna, 2009). In Pin1  
knockout mice, embryonic fibroblasts show a cytokinesis  
delay, and depletion of Pin1 from HeLa cells also causes  
cytokinesis defects. Pin1 is also deregulated in many tumors,  
including breast, prostate and lung cancer (Bao et al.,  
2004). Overexpression of Pin1 promotes tumor growth, 
while inhibition of Pin1 causes tumor cell apoptosis.  
Therefore, many Pin1 inhibitors have been developed and  
could be used as a novel type of anticancer drug by block- 
ing cell cycle progression (Xu and Etzkorn, 2009). In fact,  
Cep55 itself is found to be upregulated in breast, colorectal  
and lung cancers, and Cep55 could act as a novel breast  
cancer-associated antigen (Inoda et al., 2009). 
Not surprisingly, both Plk1 and Rho proteins are long  
known to be implicated in cancer. An example is the rela- 
tionship between Plk1 and p53. Plk1 depleted cells un- 
dergo apoptosis, activate caspase 3 and form fragmented  
nuclei (Liu and Erikson, 2003). Plk1 is later found to  
physically interact with p53 (through both coimmunopre- 
cipitation and colocalization studies) and inhibit p53’s  
pro-apoptotic function (Ando et al., 2004). Plk1 might  
negatively regulate p53 through Topors, a ubiquitin and  
SUMO E3 ligase (Yang et al., 2009). Plk1 phosphorylates  
Topors on Ser718 in vivo, and phosphorylated Topors in- 
hibits p53’s sumoylation, while enhancing its ubiquitina- 
tion (Yang et al., 2009). Another target of Plk1 to regulate  
p53 might be Mdm2, as Plk1 also phosphorylates Mdm2 at  
Ser260, thus stimulating Mdm2-mediated p53 turnover  
(Dias et al., 2009). Moreover, Plk1 knockdown decreased  
Mdm2 protein level (Kreis et al., 2009). On the other hand,  
using both p53 binding-defective human papillomavirus  
type-16 E6, and p53 RNAi, Incassati et al. (2006) show  
that p53 represses Plk1 expression, suggesting that Plk1 is  
a target of p53. Thus Plk1 and p53 may form a feedback  
loop to function in tumorigenesis. Other members of the  
p53 family include p63 and p73, both of which regulate  
cell survival and apoptosis in tumors. Plk1 phosphorylates  
p63 at Ser52, which decreases p63’s protein stability and  
suppresses apoptosis (Komatsu et al., 2009). Plk1 interacts  
and colocalizes with p73, and phosphorylates p73 at Thr27  
(Koida et al., 2008; Soond et al., 2008). The CDK inhibitor  
p21WAF1/CIP (referred to as p21 afterwards) is induced by  
p73 in HeLa cells (p53-deficient), and the long-term sup- 
pression of Plk1 increases p21 protein level (Kreis et al.,  
2009). These data strongly suggest a relationship between  
Plk1 and p53 protein families. 
As Plk1 plays a pivotal role in regulating mitosis, Plk1 
is upregulated in many tumors, such as melanomas and 
lymphomas, and could be used as a prognostic marker for 
some cancers (Strebhardt and Ullrich, 2006). Plk1 has two 
functional distinct domains, thereby providing investiga-
tors two targets within the same protein to develop 
anti-proliferative drugs. The small molecule inhibitors that 
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have been developed against Plk1 have been useful in dis-
secting its cellular functions and might be useful in the 
clinic. For instance, BI 2536 is developed as an anti-cancer 
drug that blocks Plk1 activity with high potency in vitro 
and in vivo (Mross et al., 2008). 
Rho GTPase functions in a broad spectrum of cell me-
tabolism, including cytoskeleton dynamics, cell cycle pro-
gression, transcriptional regulation and cell survival, which 
are all important for tumorigenesis (Vega and Ridley, 
2008). RhoA is shown to be involved in all stages of can-
cer progression. In breast cancers, in particular, RhoA is 
not only upregulated, but also involved in the tumor me-
tastasis (Lin and van Golen, 2004). The RhoA/ROCK sig-
naling pathway has been proposed to regulate actomy-
osin-based cortical contractility that leads to cell invasion 
(Vega and Ridley, 2008). Thus it is not surprising to find 
that RhoA protein levels are significantly increased in 
breast, lung and colon cancers (Gomez del Pulgar et al., 
2005).  
RhoA GEF Ect2 is a proto-oncogene. Ect2 is found to 
be overexpressed in glioma patients (Sano et al., 2006). In 
these patients, RhoA activation is broadened, and cytoki-
nesis initiation is affected, both of which correlate with 
Ect2’s function in RhoA regulation. The other activator, 
MyoGEF, is highly expressed in invasive breast cancer cell 
lines and infiltrating ductal carcinomas. It regulates the 
invasion activity of MDA-MB-231 breast cancer cells 
through activation of RhoA and RhoC (Wu et al., 2009). 
DLC1 (Deleted in Liver Cancer 1) encodes a RhoGAP, and 
has been identified as a tumor suppressor gene that is de-
leted in cancers of the breast, colon and lung (Xue et al., 
2008). Other GAPs, such as DLC2, DLC3, p190RhoGAP 
and GRAF are also implicated in cancer progression. 
As far as RhoA effectors are concerned, so far there is 
no evidence showing that Citron is involved in tumor, but 
Citron interacting protein Kif14 is overproduced in breast 
and lung cancers (Normand and King, 2010). ROCK is 
upregulated in cancers. Moreover, ROCK not only inter-
acts with p21 in vivo in Ras-transformed cells (Lee and 
Helfman, 2004), but also upregulates p21 in prostate can-
cer cells (Xiao et al., 2009). Upon stimulating a condi-
tional active ROCK-estrogen receptor fusion protein, cy-
clin D1, p21, cyclin A levels are elevated, while p27Kip1 
levels are reduced (Croft and Olson, 2006). Current thera-
peutic strategies targeting Rho signaling in cancer have 
been twofold: one directly targets Rho, the other focuses 
on inhibiting Rho downstream effectors, such as ROCK. 
The ROCK inhibitor fasudil not only is used to treat car-
diovascular diseases, but also inhibits tumor progression in 
human and rat tumor models (Ying et al., 2006). Another 
ROCK inhibitor, Y-27632, can block Ras-mediated trans-
formation of NIH3T3 cells (Sahai et al., 1999).  
Outlooks and future directions 
Are there more RhoA activators? Ect2, MyoGEF, 
p0071 are among the RhoA activators that have been 
identified so far. But to date over 70 RhoGEF, 60 
RhoGAPs have been identified (Vega and Ridley, 2008), 
suggesting that there might be more RhoA activators. In 
light of the intricate interplay between Plk1 and RhoA, 
we speculate that more RhoA activators would turn out to 
be regulated by Plk1. 
Upon cytokinesis completion, RhoA may need to be in-
activated for cleavage furrow disassembly (Chalamalasetty 
et al., 2006). But how is RhoA inactivated? Recent evi-
dence suggests that it may be regulated at the protein level. 
RhoA is shown to be ubiquitinated by Cul3-BACURD 
ubiquitin ligase complexes (Chen et al., 2009b). When 
Cul3 is lacking, RhoA degradation is affected, and actin 
stress fibers are aberrant. Dysfunction of the Cul3-BACURD 
complex attenuates the migration potential of HeLa cells 
and mouse embryonic fibroblasts, and affects convergent 
extension during gastrulation in Xenopus embryos (Chen 
et al., 2009b). However, the authors did not examine 
whether cells display any cytokinesis defects. Alternatively, 
RhoA might be inactivated by the RhoGDI. It has been 
known that GDP-Rho is prenylated and bound at the 
translation site by specific RhoGDIs until RhoGDF 
(RhoGDI-displacement factor) liberation, transported to its 
specific membrane location and activated by RhoGEF. It is 
conceivable that premature release of RhoA by RhoGDI 
will lead to RhoA deregulation. But so far only RhoGDIs 
in Dictyostelium are shown to be involved in cytokinesis 
(Imai et al., 2002; Rivero et al., 2002). Mammals have 
three isoforms of RhoGDI. Are they also involved in cyto-
kinesis? Could they also be regulated by Plk1 phosphory-
lation? These questions await further studies. 
It is now clear that cytokinesis and cancer are intricately 
linked. And targeting proteins involved in cytokinesis 
could become a common theme for tumor therapy. Further 
studies will reveal more Plk1 substrates and more RhoA 
regulating proteins that are involved in the cytokinesis 
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pathway, thus providing more targets for novel drug de-
velopment that can be taken to the clinic. 
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